Abdollahi Jahdi Sahar, Parvin Parviz, Seyedi Solaleh, Jelvani Saeid, Razzaghi Mohammad Reza
Physics Department, Amirkabir University of Technology, Tehran, Iran.
Photonics and Quantum Technologies Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.
J Lasers Med Sci. 2021 Sep 25;12:e51. doi: 10.34172/jlms.2021.51. eCollection 2021.
Spectroscopic properties of Xeloda chemodrug have been studied over varying concentrations ranging between 0.001 and 10 mg/mL, using laser-induced fluorescence (LIF) spectroscopy. The alternative photoluminescence (PL) and near infrared (NIR) measurements are carried out to authenticate the obtained results by the LIF method. The XeCl laser as the excitation coherent source with 160 mJ/pulse at 308 nm is employed for LIF measurements of the fluorophore of interest in the modular spectroscopic set-up. Xeloda as a significant chemodrug acts as a notable fluorophore. LIF, PL and NIR spectroscopy techniques are employed to investigate the spectral properties of the chemodrug in terms of concentration. The maximum LIF peak intensity of Xeloda is achieved at λ=410.5 nm and the characteristic concentration of C=0.05 mg/mL. PL signals are in good agreement with the data given by the LIF measurements. The characteristic NIR spectra of Xeloda as solid evidence of chemical bonding formation attest to fluorescence quenching at the fluorophore concentration of 0.2 mg/ mL. Besides, the spectral shift of fluorescence signals which is obtained in terms of fluorophore concentration- demonstrating as a diagnostic marker for the purpose of optimized chemotherapy. Xeloda exhibits outstanding fluorescence properties over the allowable concentration in human serum (C). These characteristics could benefit potential advantage of simultaneous laser-based imaging of cell-chemodrug interaction over in-vivo studies.
使用激光诱导荧光(LIF)光谱,研究了希罗达化疗药物在0.001至10 mg/mL不同浓度范围内的光谱特性。进行了替代光致发光(PL)和近红外(NIR)测量,以通过LIF方法验证所得结果。在模块化光谱装置中,使用波长为308 nm、脉冲能量为160 mJ/pulse的XeCl激光作为激发相干源,对感兴趣的荧光团进行LIF测量。希罗达作为一种重要的化疗药物,可作为一种显著的荧光团。采用LIF、PL和NIR光谱技术研究了该化疗药物在浓度方面的光谱特性。希罗达的最大LIF峰强度在λ=410.5 nm、特征浓度C=0.05 mg/mL时达到。PL信号与LIF测量给出的数据高度一致。希罗达的特征近红外光谱作为化学键形成的有力证据,证明了在荧光团浓度为0.2 mg/mL时的荧光猝灭。此外,根据荧光团浓度获得的荧光信号光谱位移——可作为优化化疗的诊断标志物。希罗达在人血清(C)的允许浓度范围内表现出出色的荧光特性。这些特性可能有利于在体内研究中同时进行基于激光的细胞-化疗药物相互作用成像的潜在优势。